[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355545-105":59,"doc-detail-355545-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-hereditary-genetic-mutational-landscape-of-breast-and-ovarian-cancer-in-estonia","Exploring the hereditary genetic mutational landscape of breast and ovarian cancer in Estonia","","Germline genetic testing of cancer-associated genes supports hereditary risk identification and informs early diagnosis and personalized therapy for breast cancer (BC) and ovarian cancer (OC). Analysis of routine clinical testing in Estonia covered 3,537 patients (2,856 BC, 759 OC) from 2007–2023, including 78 individuals with both cancers. Results identified 687 pathogenic/likely pathogenic variants in 668 people, with overall PV detection of 18.9%, and highlighted BRCA1 and BRCA2 plus additional multi-gene findings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-hereditary-genetic-mutational-landscape-of-breast-and-ovarian-cancer-in-estonia/355545/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-hereditary-genetic-mutational-landscape-of-breast-and-ovarian-cancer-in-estonia/355545.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What dataset and testing period were used in the study?","Question",{"text":112,"@type":113},"The study analyzed 3,537 patients who underwent routine clinical germline genetic testing in Estonia between 2007 and 2023, including 2,856 BC and 759 OC cases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the overall detection rate of pathogenic/likely pathogenic variants?",{"text":117,"@type":113},"A total of 687 pathogenic/likely pathogenic variants were found in 668 individuals, yielding an overall combined detection rate of 18.9%.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genes accounted for the most frequently detected variants?",{"text":121,"@type":113},"BRCA1 and BRCA2 were the most frequently mutated genes, with BRCA1 and BRCA2 pathogenic variants representing major portions of the total variant yield; specific BRCA1 variants (c.5266dup and c.4035del) accounted for a large share of all detected PV.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355545,1790143838,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nExploring the hereditary genetic mutational landscape of breast and ovarian cancer in Estonia  \nMikk Tooming1,2􀀍, Kadri Toome2, Kadri Rekker2, Laura Roht3,4, Piret Laidre3,  \nOlga Fjodorova2, Hanno Roomere2, Ülle Murumets2, Ustina Šamarina2, Sander Pajusalu1,2, Riina Žordania3, KristiTael3, Eve Vaidla3, Elvira Kurvinen3, NeemeTõnisson3,7,  \nMihkel Ilisson1,2, Peeter Padrik4, Jaak Lehtsaar4, Riina Kütner5, Elen Vettus6, Helen Vahar7, Pilleriin Peets8, Katrin Õunap1,3 & Tiina Kahre1,2  \nGermline genetic testing (GT) of cancer-associated genes enables the identification of hereditary risk in breast (BC) and ovarian cancer (OC) patients, supporting early diagnosis and personalized treatment strategies. In this study, we analyzed data from 3,537 patients who underwent routine clinical GTin Estonia between 2007–2023, including 2,856 BC and 759 cases of OC. A total of 78 individuals in the study were diagnosed with both BC andOC. The mean age at diagnosis and GT was 50.4 ± 12.0 and 54.0 ± 12.5 years for BC, and 56.1 ± 14.1 and 59.4 ± 13.3 years for OC, respectively. Non-genetic medical specialists ordered most GT (66.1%) . GT increased nine-fold over the course of the study period. Altogether, 687 pathogenic/likely pathogenic variants (PV) were identified in 668 individuals (17.4% in BC, 26.0% in OC), with an overall combined PV detection rate of 18.9%. The most frequently mutated genes were BRCA1 (6.9% BC; 16.3% OC), BRCA2 (3.8%; 4.5%), and CHEK2 (3.5%; 1.7%). Two BRCA1 PV, c.5266dup and c.4035del, accounted for 29.1% of all PV detected. In addition to BRCA1/2, we identified 19 non-BRCA cancer susceptibility genes in 243 individuals and 25 novel PV, which demonstrates the importance of multi-gene NGS-based GT in Estonia for identifying hereditary cancer risk.  \nKeywords Breast cancer, Ovarian cancer, HBOC, NGS, Molecular genetics of breast and ovarian cancer  \nAccording to the World Health Organization, there were approximately 20 million new cancer cases and ~ 10 million deaths due to cancer in the year 2022, with breast cancer (BC) being the second most common cancer1. Ovarian cancer (OC) is the eighth most common cancer in women. In Estonia, on average, over 800 people develop BC, and ~ 150 OC per year, according to the Estonian National Institute for Health Development, Health Statistics and Health Research Database (HSHRD)2. Pathogenic or likely pathogenic genetic variants (PV) in cancer susceptibility genes can lead to cancer development. These PV are commonly inherited in an autosomal dominant manner, often leading to an earlier age at diagnosis3. Individual cancer risk assessment relies on family history, but limited information can lead to an underestimation of hereditary contributions to tumor development. In recent years, the clinical approach to hereditary cancer testing for at-risk patients and their family members has significantly advanced with the advent of multi-gene next-generation sequencingbased (NGS) testing4. Genetic testing (GT) and pretest consultations are becoming increasingly used by different medical specialists. A broader panel-based approach has become increasingly integrated into routine clinical care, facilitating earlier intervention opportunities, risk stratification, and personalized management for individuals and families affected by hereditary cancer syndromes4,5.  \nBRCA1/2 are the most common genes associated with HBOC6. They encode proteins that play a crucial role in tumor suppression3. Carriers of BRCA1/2 PV have an excessive risk of developing cancer and are eligible  \n1Department of Genetics and Personalized Medicine, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia. 2Department of Laboratory Genetics, Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia. 3Department of Clinical Genetics, Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tart","cbCaidkgc0JCz0tR","https://ap.wps.com/l/cbCaidkgc0JCz0tR","pdf",2001866,12,"English","# Study aims and background\n## Germline testing and clinical context\n## Genes linked to hereditary breast and ovarian cancer\n## Rationale for the Estonian genetic landscape\n# Methods and results (routine clinical GT in Estonia)\n## Cohort description and testing period\n## Variant yield and detection rates\n## Most frequently mutated genes and novel findings","[{\"question\":\"What dataset and testing period were used in the study?\",\"answer\":\"The study analyzed 3,537 patients who underwent routine clinical germline genetic testing in Estonia between 2007 and 2023, including 2,856 BC and 759 OC cases.\"},{\"question\":\"What was the overall detection rate of pathogenic/likely pathogenic variants?\",\"answer\":\"A total of 687 pathogenic/likely pathogenic variants were found in 668 individuals, yielding an overall combined detection rate of 18.9%.\"},{\"question\":\"Which genes accounted for the most frequently detected variants?\",\"answer\":\"BRCA1 and BRCA2 were the most frequently mutated genes, with BRCA1 and BRCA2 pathogenic variants representing major portions of the total variant yield; specific BRCA1 variants (c.5266dup and c.4035del) accounted for a large share of all detected PV.\"}]","Exploring the hereditary genetic mutational landscape of breast and ovarian cancer in Estonia | PDF",1790119785,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d735e5f33d108b1059d3a0d1828d081e.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba250a195d941e50955457948883c21e.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a25a9dfc709cd4865f1816273a21729f.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a500184a8f2e28601e4f4046d05fa04.webp",980,1287]